Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 5 , Pages 621-624, May 2006

Less Is More: Inpatient Management of a Child With Complex Pharmacotherapy

Dr. Kratochvil is with the Department of Psychiatry, University of Nebraska Medical Center, Omaha; Dr. Varley is with the University of Washington, Seattle; Dr. Cummins is with the Childrenapos;s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; and Dr. Martin is with the Yale Child Study Center, New Haven, CT

Accepted 19 December 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil receives grant support from, is a consultant to, and/or member of the speakerapos;s bureau of Eli Lilly, Shire, Cephalon, Organon, AstraZeneca, and Pfizer. Dr. Varley is on speakerapos;s bureau of McNeil and Novartis and is a consultant to Shire Pharmaceuticals. Over the past 5 years, Dr. Martin has received honoraria and/or travel support from Eli Lilly and Janssen Pharmaceuticals. Dr. Cummins has no financial relationships to disclose.

PII: S0890-8567(09)61210-7

doi:10.1097/01.chi.0000205707.78818.a6

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 5 , Pages 621-624, May 2006

Article Tools